Melanoma antigen preferentially expressed in tumors

BE0010493ProteinHumansPRAME

Substrate-recognition component of a Cul2-RING (CRL2) E3 ubiquitin-protein ligase complex, which mediates ubiquitination of target proteins, leading to their degradation (PubMed:21822215, PubMed:26138980). It is acted on by 1 drug in DrugBank.

Gene name
PRAME
UniProtKB entry
P78395Swiss-Prot
Cellular location
Nucleus
Residues / weight
509 residues · 57,889 Da
Also known as
MAPE · OIP-4 · OIP4 · Opa-interacting protein 4 · Preferentially expressed antigen of melanoma

Resolves to

Protein
UniProtP78395UniProt namePRAME_HUMAN
Gene
HGNCHGNC:9336NCBI Gene23532GeneCardsPRAME
Pharmacology
KEGGhsa:23532
Drugs

What you can answer from here — as of October 31, 2023

1DrugApproved to experimental, with action, bond type and pharmacological action
Sign in
2Clinical trialsTrials of drugs acting on it, by phase and status
Sign in
3GO termsFunction, process and component, as structured annotations
Sign in
2Pfam domainsDomain architecture mapped to Pfam families and clans
Sign in
2+ReferencesStructured and connected to the statements they support
Sign in

Which compounds in development act on Melanoma antigen preferentially expressed in tumors, and which indications are they being tested in?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In